Evidence map›Paper›PMID 37757762›Full record

ArticleNeonatology2023

Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study.

Hiroki Kitaoka, Takaaki Konishi, Yoshihiko Shitara, Atsushi Ito, Kohei Kashima, Asahi Fujita, Hiroki Matsui, Motohiro Kato, Naoto Takahashi, Hideo Yasunaga

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neonatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hiroki KitaokaDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Takaaki KonishiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Yoshihiko ShitaraDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Atsushi ItoDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Kohei KashimaDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Asahi FujitaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Motohiro KatoDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Naoto TakahashiDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
University of Tokyo Hospital · JPUniversity of Tokyo Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMilrinone is administered after patent ductus arteriosus (PDA) ligation to prevent and treat postoperative hemodynamic instability (i.e., postligation cardiac syndrome). We aimed to explore the effectiveness of milrinone on in-hospital outcomes in infants who underwent PDA ligation using a nationwide inpatient database in Japan.

methodsUsing the Japanese Diagnosis Procedure Combination database, we identified patients who received milrinone after PDA ligation (n = 428) in neonatal intensive care units between July 2010 and March 2021 and those who did not (n = 3,392). We conducted a 1:4 propensity score-matched analysis with adjustment for background characteristics (e.g., gestational age, birth weight, comorbidities, preoperative treatments, and hospital background) to compare morbidities (bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity), mortality, total hospitalization costs, and other outcomes. For sensitivity analysis, we performed an overlap propensity score-weighted analysis.

resultsIn-hospital morbidity, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis occurred in 58%, 48%, 9.5%, and 7.1% of patients, respectively; the in-hospital mortality was 5.4%. After 1:4 propensity score matching, no significant difference was observed regarding mortality (7.1 vs. 5.7%), in-hospital morbidity (55 vs. 50%), bronchopulmonary dysplasia (44 vs. 41%), intraventricular hemorrhage (7.8 vs. 9.1%), necrotizing enterocolitis (8.5 vs. 8.9%), retinopathy of prematurity (21 vs. 22%), or total hospitalization costs (median: approximately 86,000 vs. 82,000 US dollars) between milrinone users (n = 425) and nonusers (n = 1,698). Sensitivity analyses yielded consistent results.

conclusionsMilrinone use after PDA ligation was not associated with improved in-hospital outcomes, such as mortality and morbidity.

Indexed as

Bronchopulmonary DysplasiaDuctus Arteriosus, PatentEnterocolitis, NecrotizingRetinopathy of PrematurityCerebral HemorrhageHumansInfantInfant, NewbornInfant, PrematureLigationMilrinoneRetrospective StudiesMilrinoneBronchopulmonary dysplasiaCardiovascular functionExtremely low birth weight infantsMortalityPatent ductus arteriosus

Identifiers

PMID37757762
PMCPMC10711761
OpenAlexW4387116035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.